MIMVaC-Africa initiative for an effective malaria vaccine
World Malaria Day:
MIMVaC-Africa initiative for an effective malaria vaccine
Ouagadougou, April 23, 2021.
MIMVaC-Africa is a large consortium of a dozen universities and institutes around the world committed to the search for vaccines for a malaria-free world. Launched in March 2020, this consortium, largely funded by the European Union through the EDCTP program, is coordinated by the Groupe de Recherche Action en Santé (GRAS) which is based in Ouagadougou.
April 25 is International Malaria Day. It is an opportunity for all humanity and all actors working in the field of health to reflect in depth on this tropical disease, more than tragic, which bereaves millions of families across the planet and in particular in sub-Saharan Africa.
To realize this, it is important to know that every two minutes, a child under the age of five (05) dies of malaria in Africa.
The latest WHO World Malaria Report (2020) has once again reviewed the major issues related to malaria over the past two decades. Despite the satisfactory results of 1.5 billion cases and 7.6 million deaths averted, progress unfortunately remains at a standstill. 228 million cases and 400,000 deaths are still occurring.
This report draws the attention of the world and policymakers with alarming numbers in Africa in particular. Of the 228 million cases in 2019 globally, about 94% of cases are on the continent. Women and children are the main victims. 11.6 million pregnant women living in 33 African countries (with moderate-high transmission), were infected with malaria (35% of all pregnancies).
A sad situation that leads to a high case fatality rate. About 95% of malaria deaths worldwide come from 31 countries. Nigeria (23%), the Democratic Republic of Congo (11%), the United Republic of Tanzania (5%), Mozambique (4%), Niger (4%), and Burkina Faso (4%) together account for about 51% of all malaria deaths worldwide in 2019.
In Burkina Faso, despite multiple efforts by the government, technical and financial partners, and the international community, malaria remains the main cause of consultations and mortality among children under five and pregnant women. It is the least affluent social strata that pay the heaviest price.
Considered as a disease of poverty, malaria greatly increases the impoverishment of our communities. Household expenses related to case management, loss of productivity, school and work absenteeism, dangerously weaken the purchasing power of the inhabitants.
Faced with this gloomy picture of malaria in Burkina Faso in particular and in sub-Saharan Africa in general, GRAS acts as a real actor in the fight against malaria through medical research in close collaboration with its national, sub-regional and international partners.
On the occasion of the World Malaria Day celebrated on April 25, 2021, the GRAS research institute would like to underline the important role it plays in health research, in this case in the search for an effective vaccine, the development of new generations of antimalarial drugs and the development of innovative strategies to improve access to diagnostic tools and effective antimalarial treatments. The institute is actively involved in the evaluation of a large part of the more than 20 vaccine candidates that are under study worldwide.
The solid experience and wealth of expertise of the men and women who make up GRAS, the quality of its results and the loyalty of its commitments have enabled it to build up a great deal of trust, thus forging quality partnerships at both national and international levels.
It is this intense activity that has led the institute to head the important Consortium called MIMVaC-Africa. This is a multi-stakeholder initiative aimed at fostering the clinical development of effective vaccine candidates against different stages of the malaria microbe. Results are expected by the end of 2025.
It is a large interdisciplinary coalition of leading vaccine developers, clinical trial experts, and malaria researchers from academia, industry, and NGOs. They are: Groupe de Recherche Action en Santé (GRAS) in Burkina Faso, Centre de Recherches Médicales de Lambaréné (CERMEL) in Gabon, Manhiça Foundation in Mozambique, Ifakara Health Institute (IHI) in Tanzania, Eberhard Karls Universität Tübingen (EKUT) in Germany, Oxford University (The Chancellor, the Masters and the Scholars of the University of Oxford (UOXF) in the United Kingdom, the European Vaccine Initiative (EVI) in Germany, Leiden University Medical Center (LUMC) in the Netherlands, Luxembourg Institute of Health (LIH) in Luxembourg, and Osaka University in Japan.
Through Grant Agreement No. RIA2018SV-2310, MIMVaC-Africa receives financial support from EDCTP2 (European and Developing Countries Clinical Trials Partnership), an organization supported by European Union funding.
Vaccine candidates shortlisted for MIMVaC-Africa are
– Pre-erythrocytic vaccine candidates (Development phase in the liver of the malaria microbe)
– R21 combined with Matrix-M (product of Oxford University, UK)
– Chemically attenuated whole sporozoite vaccine; PfSPZ CVac (product of Sanaria, USA)
– ME-TRAP vectors (Oxford University, UK)
– Blood-stage candidates (the developmental phase in the blood of the malaria microbe)
– PfRH5 with Matrix-M adjuvant (University of Oxford, UK)
– NPC-SE36 with cpG adjuvant (from Osaka University, Japan).
Research on these different vaccine candidates is ongoing in the coalition structures, with the ambition and purpose of definitively solving the problem of malaria in the world.
GRAS takes this opportunity to reiterate its gratitude to the State of Burkina Faso through the Ministry of Higher Education, Scientific Research and Innovation and the Ministry of Health. It also extends this gratitude to all other national and international partners who accompany it in the daily implementation of its activities for the common fight for a world without malaria.
The Groupe de Recherche Action Santé (GRAS) is a biomedical research institute under private law in Burkina Faso, created in 2008 and accredited by the Ministry of Higher Education, Scientific Research and Innovation (MESRSI). It has agreements signed with the Ministry of Health and the National Center for Scientific and Technological Research (CNRST). The GRAS activities extend to many other pathologies that constitute a public health problem in sub-Saharan Africa such as: Shigellosis (bacillary dysentery), Bilharzia, Typhoid fever, Covid-19, etc.
Website: www.gras.bf; https://www.mimvac-africa.org/
email : firstname.lastname@example.org
Tel: +226 25 35 56 90
Contact persons :
– Dr. Sodiomon Bienvenu SIRIMA, MIMVaC-Africa Coordinator, tel: 70200444, email: email@example.com
– Dr San Maurice OUATTARA, Project Manager MIMVaC-Africa, Tel : 70093351 Email : firstname.lastname@example.org